Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache

Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase is a phase 3, randomised interventional study registered as NCT06961201 by Changchun GeneScience Pharmaceutical Co., Ltd., with a registry enrolment figure of 94 participants, started 2025-05-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Nano-crystalline Megestrol Acetate Oral Suspension; standard treatment. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy. Primary outcome: The proportion of subjects with improved appetite based on A/CS-12 assessment; The proportion of subjects with a relative increase in BMI from baseline. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) (according to the Veterans Administration Lung Study Group (VALG) staging system)". Sites: China. No results are recorded here; the registry entry is the source.